HBM Healthcare Investments AG

Equities

HBMN

CH0012627250

Investment Management & Fund Operators

Market Closed - Swiss Exchange Other stock markets 11:30:56 2024-09-12 am EDT			5-day change	1st Jan Change
168.60 ^CHF	-1.40%		-4.20%	-7.67%

Jul. 25	Chemomab Therapeutics to Raise $10 Million From Private Placement; Shares Fall	MT
Jul. 19	HBM Healthcare Investments AG Reports Earnings Results for the First Quarter Ended June 30, 2024	CI

HBM Healthcare Investments : Successful debut on the stock exchange for HBM portfolio company Longboard Pharmaceuticals

March 15, 2021 at 01:49 am EDT

EQS Group-Ad-hoc: HBM Healthcare Investments AG / Key word(s): IPO
Successful debut on the stock exchange for HBM portfolio company Longboard Pharmaceuticals

15-March-2021 / 06:46 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 KR
The issuer is solely responsible for the content of this announcement.

Longboard Pharmaceuticals (Nasdaq: LBPH), a private company in the portfolio of HBM Healthcare Investments, completed its IPO last Friday. The company raised USD 80 million in new capital by issuing 5 million shares at a price of USD 16.00 each. On the first day of trading, the share price closed at USD 16.65 (+4.1%).

HBM Healthcare Investments invested USD 10 million in Longboard Pharmaceuticals in October 2020 and increased its stake by a further USD 8 million in the IPO. Following the IPO, HBM Healthcare Investments holds 1.88 million shares with a total value of USD 31.3 million.

Longboard Pharmaceuticals focuses on the development of novel, transformative drugs for neurological diseases. The most advanced compound, LP352, an oral, centrally acting 5-HT2c superagonist, is being tested for the potential treatment of developmental and epileptic encephalopathies such as Dravet syndrome, Lennox-Gastaut syndrome and other epileptic disorders.

End of ad hoc announcement

Language:	English
Company:	HBM Healthcare Investments AG
	Bundesplatz 1
	6300 Zug
	Switzerland
Phone:	+41438887171
Fax:	+41438887172
E-mail:	info@hbmhealthcare.com
Internet:	https://www.hbmhealthcare.com
ISIN:	CH0012627250
Valor:	1262725
Listed:	SIX Swiss Exchange
EQS News ID:	1175438


End of Announcement	EQS Group News Service

1175438 15-March-2021 CET/CEST

Latest news about HBM Healthcare Investments AG

Chemomab Therapeutics to Raise $10 Million From Private Placement; Shares Fall	Jul. 25	MT
HBM Healthcare Investments AG Reports Earnings Results for the First Quarter Ended June 30, 2024	Jul. 19	CI
HBM Healthcare Investments Swings to Profit in Q1	Jul. 19	MT
Cartesian Therapeutics Secures $130 Million Private Placement Equity Financing	Jul. 02	MT
HBM Healthcare Flags NAV Boost from Yellow Jersey-Johnson & Johnson Deal	May. 28	MT
HBM Healthcare Investments' Portfolio Company to Buy Laboratorios Biopas Group	May. 23	MT
HBM Healthcare Investments' Net Loss Narrows in FY24	May. 09	MT
HBM Healthcare Investments AG Reports Earnings Results for the Full Year Ended March 31, 2024	May. 08	CI
Tranche Update on HBM Healthcare Investments AG's Equity Buyback Plan announced on July 5, 2023.	May. 08	CI
HBM Healthcare Investments Warns of CHF1 Million Loss for FY24	Apr. 03	MT
Tranche Update on HBM Healthcare Investments AG's Equity Buyback Plan announced on July 5, 2023.	Jan. 30	CI
HBM Healthcare Investments AG Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Jan. 22	CI
HBM Healthcare Investments Logs Lower Fiscal Q3 Loss	Jan. 22	MT
HBM Healthcare Investments Warns of FY24 Nine-month Net Loss	Jan. 04	MT
AbbVie to Buy Cancer-focused ImmunoGen for $10.1 Billion	Nov. 30	MT
Kepler Cheuvreux Lowers Price Target on HBM Healthcare Investments, Maintains Buy Recommendation	Nov. 21	MT
HBM Healthcare Investments Launches Share Buyback	23-10-16	MT
HBM Healthcare Investments AG Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	23-10-16	CI
HBM Healthcare Investments Logs Higher Fiscal H1 Loss	23-10-16	MT
Tranche Update on HBM Healthcare Investments AG's Equity Buyback Plan announced on July 5, 2023.	23-10-16	CI
HBM Healthcare Investments Flags Fiscal H1 Loss	23-10-03	MT
HBM Healthcare Investments AG Reports Earnings Results for the First Quarter Ended June 30, 2023	23-07-21	CI
HBM Healthcare Investments' Ficsal Q1 NAV Per Share Declines	23-07-21	MT
HBM Healthcare Investments AG commences an Equity Buyback Plan under the authorization approved on June 10, 2022.	23-07-05	CI
HBM Healthcare's Portfolio Company Cathay Biotech to Sell Shares for CNY6.6 Billion	23-06-26	MT

Chart HBM Healthcare Investments AG

Duration

Period

More charts

Company Profile

HBM Healthcare Investments AG is a Switzerland-based venture capital company investing in emerging companies, mainly from the biotechnology and human medicine, diagnostics, as well as medical technology sectors. The Company focuses on unlisted companies, with two-thirds of assets being invested in private companies that offer high value-creation potential. As a holding company, it is involved in the acquisition, disposal and management of a diversified portfolio, as well as in financing and supporting the portfolio firms as a key partner. It focuses on companies with products either at an advanced stage of development or already available on the market. The primary investment areas are Western Europe and the United States. The Company's portfolio includes approximately 25 companies. As of March 31, 2012, the Company had six wholly owned subsidiaries, including three subsidiaries on Cayman Islands, two Barbados-based subsidiaries and a subsidiary in the United States.

Employees

700

Sector

Investment Management & Fund Operators

Calendar

2024-10-20 - Q2 2025 Earnings Release

More about the company